252 related articles for article (PubMed ID: 25255430)
1. Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid.
Messingham KN; Holahan HM; Frydman AS; Fullenkamp C; Srikantha R; Fairley JA
PLoS One; 2014; 9(9):e107725. PubMed ID: 25255430
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
3. Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity.
Emtenani S; Linnemann BE; Recke A; von Georg A; Goletz S; Schmidt E; van Beek N
J Dermatol Sci; 2024 May; 114(2):64-70. PubMed ID: 38582700
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
5. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.
Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C
Front Immunol; 2019; 10():1919. PubMed ID: 31474990
[TBL] [Abstract][Full Text] [Related]
6. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.
Hashimoto T; Ohzono A; Teye K; Numata S; Hiroyasu S; Tsuruta D; Hachiya T; Kuroda K; Hashiguchi M; Kawakami T; Ishii N
Br J Dermatol; 2017 Jul; 177(1):141-151. PubMed ID: 27716903
[TBL] [Abstract][Full Text] [Related]
7. Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.
Messingham KN; Pietras TA; Fairley JA
G Ital Dermatol Venereol; 2012 Jun; 147(3):251-7. PubMed ID: 22648326
[TBL] [Abstract][Full Text] [Related]
8. IgE autoantibodies against the intracellular domain of BP180.
Dresow SK; Sitaru C; Recke A; Oostingh GJ; Zillikens D; Gibbs BF
Br J Dermatol; 2009 Feb; 160(2):429-32. PubMed ID: 18808416
[TBL] [Abstract][Full Text] [Related]
9. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
[TBL] [Abstract][Full Text] [Related]
10. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
11. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
Iwata Y; Komura K; Kodera M; Usuda T; Yokoyama Y; Hara T; Muroi E; Ogawa F; Takenaka M; Sato S
Arch Dermatol; 2008 Jan; 144(1):41-8. PubMed ID: 18209167
[TBL] [Abstract][Full Text] [Related]
12. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
[TBL] [Abstract][Full Text] [Related]
13. The Eotaxin-1/CCR3 Axis and Matrix Metalloproteinase-9 Are Critical in Anti-NC16A IgE-Induced Bullous Pemphigoid.
Jordan TJM; Chen J; Li N; Burette S; Wan L; Chen L; Culton DA; Geng S; Googe P; Thomas NE; Diaz LA; Liu Z
J Immunol; 2023 Oct; 211(8):1216-1223. PubMed ID: 37672029
[TBL] [Abstract][Full Text] [Related]
14. IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.
Freire PC; Muñoz CH; Stingl G
Br J Dermatol; 2017 Dec; 177(6):1644-1653. PubMed ID: 28868796
[TBL] [Abstract][Full Text] [Related]
15. The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.
Messingham KN; Crowe TP; Fairley JA
Front Immunol; 2019; 10():2331. PubMed ID: 31636640
[TBL] [Abstract][Full Text] [Related]
16. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.
Fairley JA; Fu CL; Giudice GJ
J Invest Dermatol; 2005 Sep; 125(3):467-72. PubMed ID: 16117787
[TBL] [Abstract][Full Text] [Related]
17. IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid.
Delaporte E; Dubost-Brama A; Ghohestani R; Nicolas JF; Neyrinck JL; Bergoend H; Janin A; Capron M
J Immunol; 1996 Oct; 157(8):3642-7. PubMed ID: 8871665
[TBL] [Abstract][Full Text] [Related]
18. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230).
Ghohestani RF; Cozzani E; Delaporte E; Nicolas JF; Parodi A; Claudy A
J Clin Immunol; 1998 May; 18(3):202-9. PubMed ID: 9624579
[TBL] [Abstract][Full Text] [Related]
19. Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.
Emtenani S; Yuan H; Lin C; Pan M; Hundt JE; Schmidt E; Komorowski L; Stanley JR; Hammers CM
Br J Dermatol; 2019 May; 180(5):1099-1106. PubMed ID: 30315657
[TBL] [Abstract][Full Text] [Related]
20. Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score.
Holtsche MM; Goletz S; van Beek N; Zillikens D; Benoit S; Harman K; Walton S; English J; Sticherling M; Chapman A; Levell NJ; Groves R; Williams HC; König IR; Schmidt E;
Br J Dermatol; 2018 Oct; 179(4):918-924. PubMed ID: 29607480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
